China NMPA grants breakthrough therapy designation to Kelun-Biotech’s sacituzumab tirumotecan in combo with immunotherapy pembrolizumab for first-line treatment of PD-L1-positive NSCLC ...
PD-1 inhibitors versus PD-L1 inhibitors in PD-L1–negative advanced non-small cell lung cancer: A meta-analysis of survival outcomes. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech' or the 'Company,' 6990.HK) today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, ...
Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has shared an update. Shanghai Henlius Biotech has initiated a first-in-human phase 1 ...
Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a ...
By ending its agreement with ImmuneOnco, Instil is also handing back the other asset from the licensing deal: IMM27M, a next-gen anti-CTLA-4 antibody that ImmuneOnco had taken into phase 1 trials as a ...
BioNTech’s oncology strategy centers on a bispecific antibody that the company envisions as the backbone of many potential drug combinations for many types of cancer. Bristol Myer Squibb is buying ...
A global study reveals that cutting-edge cancer immunotherapies, while lifesaving, carry a hidden risk: they may trigger cholestasis, a serious liver condition where bile flow stalls. Analyzing 634 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback